The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK 1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK 1 cells. The basal-to-apical transport of 
Docetaxel ("Taxotere") [(2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate] (C 43 H 53 NO 14 ⋅3H 2 O (861.94); Fig.  1 ), a semi-synthetic analog of paclitaxel ("Taxol"), was developed in 1981. It promotes microtubule polymerization leading to cell cycle arrest at G2/M, apoptosis and finally cytotoxicity. 1, 2) Tubulin normally present in cells is in dynamic equilibrium between tubulin dimers and microtubules. Vinca alkaloids and colchicine inhibit tubulin polymerization and thus lead to disruption of the mitotic spindle.
3) Docetaxel has been found to be superior to paclitaxel in a number of experimental models and this can be explained by improved cellular uptake and microtubule stabilization.
2) Docetaxel has significant activity in breast, non-small cell lung, ovarian and head and neck cancers.
2, 4-7) Docetaxel has undergone phase I studies in a number of dosage regimens mainly in North America, Europe and Japan, and has already been approved in these countries for use in treatment of breast and non-small cell lung cancer. 8) Anticancer drugs are usually applied in combination with other anticancer drugs to ensure higher efficacy. Anticancer drugs which have been used in combination with docetaxel include cisplatin, carboplatin, 5-fluorouracil, doxorubicin, gemcitabine, etoposide, cyclophosphamide, ifosfamide, topotecan and irinotecan. 2) In combination therapy, drug-drug interaction may arise as the result of altered pharmacokinetics and pharmacodynamics of the drugs involved. However, no significant pharmacokinetic drug-drug interactions with docetaxel have been reported, with the exception of doxorubicin 9) and etoposide, 10) and actually little information is available regarding pharmacodynamic drug-drug interactions involving docetaxel.
Previously, we established LLC-GA5-COL150 cells 11, 12) selectively overexpressing human P-glycoprotein (P-gp), which is a key protein in the excretion of xenobiotics and the multidrug resistance (MDR) of tumor cells, on the apical membrane by transfection of MDR1 cDNA into porcine kidney epithelial LLC-PK 1 cells. This cell line has been shown to form monolayers with tight junctions, and has been used for direct assessment of P-gp-mediated drug transport. [11] [12] [13] [14] [15] Using this cell line, we demonstrated the transport of vinblastine and doxorubicin via P-gp and the 4 To whom correspondence should be addressed. E-mail: okumurak@kobe-u.ac.jp 5 Present address: Department of Drug Informatics, Faculty of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado, Saitama 350-0290. inhibitory effects of MDR modulators, i.e., cyclosporin A and SDZ PSC 833 (PSC833). Based on these findings, we predicted the clinical effectiveness of MDR modulators for cancer chemotherapy. 14) Here, the interaction of docetaxel with human P-gp was examined by using LLC-GA5-COL150 cells. All other chemicals were of the highest purity available. Cells and cell culture LLC-PK 1 and LLC-GA5-COL150 cells transfected with human MDR1 cDNA were used. The expression of P-gp on the apical membrane of LLC-GA5-COL150 cells was confirmed previously by immunostaining and electron microscopic immunocytochemistry using the monoclonal antibody MRK16. 11, 12) Both of these cell lines were maintained in complete medium consisting of Medium199 (Dainippon Pharmaceutical Co., Ltd., Osaka) supplemented with 10% fetal bovine serum (BioWhittaker, Walkersville, MD) without antibiotics. Monolayer cultures were grown in an atmosphere of 5% CO 2 -95% air at 37°C, and were subcultured every 4 and 7 days for LLC-PK 1 and LLC-GA5-COL150 cells, respectively, with 0.02% EDTA and 0.05% trypsin (Gibco BRL, Life Technologies, Inc., Grand Island, NY).
MATERIALS AND METHODS

Chemicals
Transcellular transport and intracellular accumulation of [
14 C]docetaxel LLC-PK 1 and LLC-GA5-COL150 cells were seeded on microporous polycarbonate membrane filters ("Transwell" 3414, Costar, Cambridge, MA) at a cell density of 4×10 5 and 5×10 5 cells/cm 2 , respectively. Cells were cultured in 2.6 and 1.5 ml of Medium199 supplemented with 10% fetal bovine serum and 150 ng/ml colchicine for LLC-GA5-COL150 cells outside and inside the chamber, respectively, in an atmosphere of 5% CO 2 -95% air at 37°C for 3 days. The experiments were performed using the same procedure as described previously. [11] [12] [13] [14] [15] The transcellular transport assay system using LLC-PK 1 and LLC-GA5-COL150 cells is shown schematically in Fig. 2 . At 3 h before transport , and that on the receiver side was replaced with 2 ml of fresh medium alone. In the experiments to examine the time course and temperature dependency of [ 14 C]docetaxel transport, docetaxel was used at 10 µM to saturate its directional transport in LLC-PK 1 cells. The monolayers were incubated at 37°C, and aliquots (25 µl) of the medium on the receiver side were taken at the indicated time points. To examine their effects on the transcellular transport of [
14 C]docetaxel, MDR modulators were added to both sides of the monolayers 1 h before the experiments. The incubation medium also contained the same concentration of MDR modulators. The paracellular leakage was estimated from the amount of [ 3 H]inulin appearing on the receiver side, and it was less than 1% of the total radioactivity per hour. For accumulation studies, the medium was aspirated off at the end of the incubation period, and the monolayers were rapidly washed twice with ice-cold phosphate-buffered saline on each side. The filters with monolayers were detached from the chambers, and the cells on filters were lysed with 1 ml of 0.3 N NaOH. The levels of radioactivity of the collected media and lysed cells were counted in 3 ml of ACS II (Amersham International) by liquid scintillation counting (Beckman, LS6000TA, Fullerton, CA) and are presented as percentages of the total radioactivity. (Fig. 5) .
Inhibitory effects of MDR modulators and daunorubicin on the transcellular transport of [
14 C]docetaxel in LLC-PK 1 cells Since LLC-PK 1 cells also endogenously expressed P-gp at markedly lower levels than LLC-GA5-COL150 cells, 11, 13, 16, 17) the inhibitory effects of MDR modulators on the transcellular transport of 0.86 µM [ 14 C]docetaxel were also examined using LLC-PK 1 cells (Fig. 6) . The basal-to-apical transport of [ 14 C]docetaxel was extensively inhibited by cyclosporin A, PSC833 and verapamil at 10, 2 and 10 µM, respectively. These concentrations were 2-to 10-fold lower than those used for LLC-GA5-COL150 cells (Fig. 4) . These MDR modulators resulted in an increase in apical-to-basal transport of [ 14 C]docetaxel and consequently in no net transport. The effects of MDR modulators were more marked in LLC-PK 1 cells than in LLC-GA5-COL150 cells. Daunorubicin, a substrate for P-gp, also suppressed the [ 14 C]docetaxel transport in a concentration-dependent manner (Fig. 7) . Similar results were also obtained with vinblastine (data not shown).
DISCUSSION
Drug-drug interactions may arise as the result of altered pharmacokinetics and pharmacodynamics of the drugs involved. Anticancer drugs are usually given in combination to ensure higher efficacy. Pharmacokinetic interactions are often caused via competitive inhibition of serum proteins, carrier proteins and enzymes. Cytochrome P450 (CYP) 3A4 may be responsible for docetaxel metabolism, [18] [19] [20] and docetaxel was shown to be highly bound by plasma proteins (>92%). 21) Therefore, drugs that are substrates of CYP3A4 or that show high binding to plasma proteins should be used with care. However, little is known regarding the carrier system for docetaxel. Recently, P-gp was found to be an important carrier protein located in the biliary canaliculi, the proximal tubules of the kidney, the intestinal and colonic epithelium as well as the capillary endothelial cells of the brain, to have protective effects against noxious xenobiotics and to act as a transporter for endogenous substances. 22, 23) Here, the interaction of docetaxel with P-gp was examined from the viewpoint of pharmacokinetic drug-drug interaction. In addition, P-gp could also be a key protein in pharmacodynamic interactions. P-gp overexpression has been demonstrated to be one of the various mechanisms of MDR in human tumors. P-gp expels anticancer drugs from tumor cells, utilizing the energy produced by hydrolysis of adenosine triphosphate (ATP). Thus, the intracellular concentration of the anticancer drugs is decreased to sublethal levels, resulting in resistance. [23] [24] [25] [26] [27] [28] This study was also performed to obtain information regarding the pharmacodynamic drug-drug interactions of docetaxel.
The basal-to-apical transport of [ C]docetaxel by these three MDR modulators after basal or apical application to LLC-GA5-COL150 cells. We demonstrated previously that cyclosporin A inhibited the P-gp-mediated transport of vinblastine and doxorubicin in LLC-GA5-COL150 cells, 14) corresponding to the increases in plasma concentration or toxicity of vinblastine 29) and doxorubicin [30] [31] [32] upon co-administration of cyclosporin A in humans. Consequently, docetaxel was demonstrated to be transported by human P-gp, like vinblastine and doxorubicin. It was expected that the co-administration of MDR modulators, such as cyclosporin A, would increase the plasma concentration of docetaxel in humans. The observation that verapamil had effects different from those of cyclosporin A and PSC833 on the basal-toapical transport of [
14 C]docetaxel in the LLC-GA5-COL150 cells may be explained by the differences in the inhibitory effects of these MDR modulators on P-gp. The present findings are similar to the previous report that itraconazole, an MDR modulator, has a slight effect on the basal-to-apical transport of [ The inhibition of [ 14 C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine (data not shown) was also found in LLC-PK 1 cells. The concentrations of MDR modulators required to provide similar inhibitory effects were lower than those in LLC-GA5-COL150 cells. These observations suggested that pharmacokinetic and pharmacodynamic interactions via P-gp might occur during combination chemotherapy including docetaxel and anticancer drugs, which are substrates of Pgp, since anthracyclines and vinca alkaloids have been used in combination chemotherapy with docetaxel. 2) In conclusion, our results demonstrated that docetaxel is transported via human P-gp. These observations suggest that pharmacokinetic and pharmacodynamic interactions via P-gp may occur in combination chemotherapy with docetaxel.
